Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab versus adalimumab in biologic-naive psoriatic arthritis
MOH_2017-05-07_000362Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in psoriatic arthritis (PsA) and plaque psoriasis comparing Ixekizumab with Adalimumab (2 arms). Started Apr 2017; status: completed.
02
Drugs
ixekizumabadalimumab
03
Conditions
psoriatic arthritis (PsA)plaque psoriasis
Beyond the preview
Go deeper on MOH_2017-05-07_000362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-07_000362.